Korean J Hematol 2010; 45(2):
Published online June 30, 2010
https://doi.org/10.5045/kjh.2010.45.2.136
© The Korean Society of Hematology
1Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.
2Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.
Correspondence to : Correspondence to Young Yiul Lee, M.D., Ph.D. Division of Hematology/Oncology, Department of Internal Medicine, Hanyang University Hospital, 17, Haeng Dang-dong, Sung Dong-gu, Seoul 133-792, Korea. Tel: +82-2-290-8334, Fax: +82-2-298-9183, leeyy@hanyang.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Essential thrombocythemia (ET) is a chronic myeloproliferative disorder with a prolonged clinical course. Since this disorder is considered to be at increased risk of thromboembolism, therapy is mainly focused on the decreased risk of thrombohemorrhagic events by use of cytotoxic agents. Anagrelide is a phosphodiesterase III inhibitor which is utilized in the treatment of ET for the reduction of platelets. However, patients treated with anagrelide might experience cardiovascular adverse effects including myocardial infarction (MI), although these events are rare. Herein, we report a case of a 30-year-old female with well controlled ET by anagrelide, who eventually developed an acute non-ST elevation myocardial infarction (MI). There has no found any cardiovascular risk factors in this ET patient, strongly suggesting that anagrelide might be the cause of MI. Therefore, cardiovascular function should be monitored in those patients prescribed with anagrelide.
Keywords Anagrelide, Essential thrombocythemia, Acute myocardial infarction
Korean J Hematol 2010; 45(2): 136-138
Published online June 30, 2010 https://doi.org/10.5045/kjh.2010.45.2.136
Copyright © The Korean Society of Hematology.
Young-Hyo Lim1, Young Yiul Lee2*, Jae Hoon Kim1, Jinho Shin1, Jae Ung Lee1, Kyung-Soo Kim1, Soon-Kil Kim1, Jeong Hyun Kim1, and Heon Kil Lim1
1Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.
2Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.
Correspondence to: Correspondence to Young Yiul Lee, M.D., Ph.D. Division of Hematology/Oncology, Department of Internal Medicine, Hanyang University Hospital, 17, Haeng Dang-dong, Sung Dong-gu, Seoul 133-792, Korea. Tel: +82-2-290-8334, Fax: +82-2-298-9183, leeyy@hanyang.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Essential thrombocythemia (ET) is a chronic myeloproliferative disorder with a prolonged clinical course. Since this disorder is considered to be at increased risk of thromboembolism, therapy is mainly focused on the decreased risk of thrombohemorrhagic events by use of cytotoxic agents. Anagrelide is a phosphodiesterase III inhibitor which is utilized in the treatment of ET for the reduction of platelets. However, patients treated with anagrelide might experience cardiovascular adverse effects including myocardial infarction (MI), although these events are rare. Herein, we report a case of a 30-year-old female with well controlled ET by anagrelide, who eventually developed an acute non-ST elevation myocardial infarction (MI). There has no found any cardiovascular risk factors in this ET patient, strongly suggesting that anagrelide might be the cause of MI. Therefore, cardiovascular function should be monitored in those patients prescribed with anagrelide.
Keywords: Anagrelide, Essential thrombocythemia, Acute myocardial infarction
Initial electrocardiograph showing T-wave inversions in leads I, aVL, and V2 through V5, which are consistent with myocardial ischemia.
Coronary angiography (CAG) and intravascular ultrasound (IVUS). (
Young Mi Seol, Bo Ran Kwon, Young Jin Choi, Kyung Woo Lee, Ho Jin Shin, Joo Seop Chung, Eun Yup Lee, Won Sik Lee, Young Don Joo, Goon Jae Cho
Korean J Hematol 2008; 43(2): 83-88Jin-Young Kim, Yoo, Jin Kim, Byung, Ha Chung, Chan, Lan You, Ji, Song Ko, Yoon, Hee Park, Hee, Je Kim, Seok Lee, Dong, Wook Kim, Woo, Sung Min, Chun, Choo Kim
Korean J Hematol 2003; 38(3): 164-168Myung-Won Lee, Jeong Suk Koh, Sora Kang, Hyewon Ryu, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Seon Young Kim, Seong Soo Kim, Deog-Yeon Jo
Blood Res 2023; 58(4): 173-180
Initial electrocardiograph showing T-wave inversions in leads I, aVL, and V2 through V5, which are consistent with myocardial ischemia.
|@|~(^,^)~|@|Coronary angiography (CAG) and intravascular ultrasound (IVUS). (